The pace of hepatitis C virus (HCV) drug development in recent years has accelerated
dramatically. For patients to benefit from these impressive advances, practitioners need …

Abstract Worldwide, an estimated 130–170 million people have HCV infection. HCV
prevalence is highest in Egypt at> 10% of the general population and China has the most …

Hepatitis C virus (HCV) is an increasing cause of morbidity and mortality in the United
States. Many of the 2.7–3.9 million persons living with HCV infection are unaware they are …

Histological assessment of the liver, and thus, liver biopsy, is a cornerstone in the evaluation
and management of patients with liver disease and has long been considered to be an …

Background The hepatitis C virus (HCV) is a major public health problem and a leading
cause of chronic liver disease. 5 An estimated 180 million people are infected worldwide. 6 …

Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma,
and liver transplantation. A better understanding of HCV disease progression and the …

Hepatitis C is of concern both to industrialized and developing countries. Preliminary
unpublished estimates of the global burden of disease (GBD) attributable to HCV‐related …

Background: Serum alanine aminotransferase (ALT) activity, the variable most commonly
measured to assess hepatic disease, fails to identify many patients with hepatic injury …

Nonalcoholic steatohepatitis (NASH) may present with increased hepatic fibrosis
progressing to end‐stage liver disease. No factors that determine increasing fibrosis and …

Background & Aims: Nonalcoholic fatty liver disease (NAFLD) is common in severely obese
subjects and can progress to cirrhosis and liver failure. Predicting advanced or progressive …